PanGen Biotech (Korea) Performance
| 222110 Stock | KRW 5,720 280.00 4.67% |
On a scale of 0 to 100, PanGen Biotech holds a performance score of 9. The company holds a Beta of -0.49, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning PanGen Biotech are expected to decrease at a much lower rate. During the bear market, PanGen Biotech is likely to outperform the market. Please check PanGen Biotech's standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to make a quick decision on whether PanGen Biotech's historical price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in PanGen Biotech are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, PanGen Biotech sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -6 B |
PanGen |
PanGen Biotech Relative Risk vs. Return Landscape
If you would invest 409,500 in PanGen Biotech on September 1, 2024 and sell it today you would earn a total of 162,500 from holding PanGen Biotech or generate 39.68% return on investment over 90 days. PanGen Biotech is generating 0.7213% of daily returns and assumes 5.8588% volatility on return distribution over the 90 days horizon. Simply put, 52% of stocks are less volatile than PanGen, and 86% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
PanGen Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PanGen Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PanGen Biotech, and traders can use it to determine the average amount a PanGen Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1231
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 222110 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.86 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.72 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average PanGen Biotech is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PanGen Biotech by adding it to a well-diversified portfolio.
PanGen Biotech Fundamentals Growth
PanGen Stock prices reflect investors' perceptions of the future prospects and financial health of PanGen Biotech, and PanGen Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PanGen Stock performance.
| Return On Equity | -24.89 | |||
| Return On Asset | -0.079 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.82) % | |||
| Current Valuation | 90.89 B | |||
| Shares Outstanding | 9.64 M | |||
| Price To Sales | 13.35 X | |||
| Revenue | 7.94 B | |||
| EBITDA | (3.07 B) | |||
| Cash And Equivalents | 8.9 B | |||
| Total Debt | 5.49 M | |||
| Debt To Equity | 1.52 % | |||
| Cash Flow From Operations | (3.32 B) | |||
| Total Asset | 43.28 B | |||
About PanGen Biotech Performance
By analyzing PanGen Biotech's fundamental ratios, stakeholders can gain valuable insights into PanGen Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PanGen Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PanGen Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PanGen Biotech Inc. operates as a specialized biologics company in South Korea. The company was founded in 1999 and is based in Suwon, South Korea. PanGen is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about PanGen Biotech performance evaluation
Checking the ongoing alerts about PanGen Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PanGen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PanGen Biotech is way too risky over 90 days horizon | |
| PanGen Biotech appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 7.94 B. Net Loss for the year was (3.31 B) with profit before overhead, payroll, taxes, and interest of 1.35 B. | |
| PanGen Biotech has accumulated about 8.9 B in cash with (3.32 B) of positive cash flow from operations. | |
| Roughly 33.0% of the company shares are owned by insiders or employees |
- Analyzing PanGen Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PanGen Biotech's stock is overvalued or undervalued compared to its peers.
- Examining PanGen Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PanGen Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PanGen Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PanGen Biotech's stock. These opinions can provide insight into PanGen Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PanGen Stock analysis
When running PanGen Biotech's price analysis, check to measure PanGen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PanGen Biotech is operating at the current time. Most of PanGen Biotech's value examination focuses on studying past and present price action to predict the probability of PanGen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PanGen Biotech's price. Additionally, you may evaluate how the addition of PanGen Biotech to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |